EGFR and non-small cell lung carcinoma: As expected, it was reported that afatinib showed a potent inhibitory activity even in in vitro models which were resistant to first-generation EGFR TKIs, and was still effective in NSCLC patients that showed no or low response to gefitinib or erlotinib [44].